JP2007509059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509059A5 JP2007509059A5 JP2006535368A JP2006535368A JP2007509059A5 JP 2007509059 A5 JP2007509059 A5 JP 2007509059A5 JP 2006535368 A JP2006535368 A JP 2006535368A JP 2006535368 A JP2006535368 A JP 2006535368A JP 2007509059 A5 JP2007509059 A5 JP 2007509059A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- heteroaryl
- compound
- aminoalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 heterocycloaryl Chemical group 0.000 claims 179
- 150000001875 compounds Chemical class 0.000 claims 79
- 125000000217 alkyl group Chemical group 0.000 claims 61
- 125000001072 heteroaryl group Chemical group 0.000 claims 47
- 125000004103 aminoalkyl group Chemical group 0.000 claims 40
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 37
- 229910052739 hydrogen Inorganic materials 0.000 claims 35
- 125000003118 aryl group Chemical group 0.000 claims 32
- 239000001257 hydrogen Substances 0.000 claims 31
- 125000000753 cycloalkyl group Chemical group 0.000 claims 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 21
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 17
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 17
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- 241001465754 Metazoa Species 0.000 claims 9
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 8
- 125000002252 acyl group Chemical group 0.000 claims 8
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 8
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000001624 naphthyl group Chemical group 0.000 claims 8
- 125000000068 chlorophenyl group Chemical group 0.000 claims 7
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 5
- 102000009929 raf Kinases Human genes 0.000 claims 5
- 108010077182 raf Kinases Proteins 0.000 claims 5
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 4
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 4
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 4
- 229940123237 Taxane Drugs 0.000 claims 4
- 229940122803 Vinca alkaloid Drugs 0.000 claims 4
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 4
- 229960005310 aldesleukin Drugs 0.000 claims 4
- 108700025316 aldesleukin Proteins 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims 4
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 4
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- HSMPSHPWCOOUJH-UHFFFAOYSA-N anilinyl Chemical group [NH]C1=CC=CC=C1 HSMPSHPWCOOUJH-UHFFFAOYSA-N 0.000 claims 4
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000005128 aryl amino alkyl group Chemical group 0.000 claims 4
- 125000001769 aryl amino group Chemical group 0.000 claims 4
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 4
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 claims 4
- 239000012965 benzophenone Substances 0.000 claims 4
- 150000005347 biaryls Chemical group 0.000 claims 4
- 235000010290 biphenyl Nutrition 0.000 claims 4
- 239000004305 biphenyl Substances 0.000 claims 4
- 125000004799 bromophenyl group Chemical group 0.000 claims 4
- 229960004117 capecitabine Drugs 0.000 claims 4
- 229960004562 carboplatin Drugs 0.000 claims 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 4
- 229960004316 cisplatin Drugs 0.000 claims 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 4
- 125000004858 cycloalkoxyalkyl group Chemical group 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 4
- 125000004367 cycloalkylaryl group Chemical group 0.000 claims 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- WVIIMZNLDWSIRH-UHFFFAOYSA-N cyclohexylcyclohexane Chemical group C1CCCCC1C1CCCCC1 WVIIMZNLDWSIRH-UHFFFAOYSA-N 0.000 claims 4
- 229960004397 cyclophosphamide Drugs 0.000 claims 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
- 229960003901 dacarbazine Drugs 0.000 claims 4
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 4
- 125000004986 diarylamino group Chemical group 0.000 claims 4
- 125000004188 dichlorophenyl group Chemical group 0.000 claims 4
- 125000004212 difluorophenyl group Chemical group 0.000 claims 4
- 125000005240 diheteroarylamino group Chemical group 0.000 claims 4
- 229960002949 fluorouracil Drugs 0.000 claims 4
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 4
- 235000008191 folinic acid Nutrition 0.000 claims 4
- 239000011672 folinic acid Substances 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 4
- 229960002584 gefitinib Drugs 0.000 claims 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 4
- 229960005277 gemcitabine Drugs 0.000 claims 4
- 125000006485 halo alkoxy phenyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000005059 halophenyl group Chemical group 0.000 claims 4
- 125000005241 heteroarylamino group Chemical group 0.000 claims 4
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 claims 4
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 4
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 4
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 4
- 229960002411 imatinib Drugs 0.000 claims 4
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 4
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 4
- 125000001041 indolyl group Chemical group 0.000 claims 4
- 125000006303 iodophenyl group Chemical group 0.000 claims 4
- 229940084651 iressa Drugs 0.000 claims 4
- 229960004768 irinotecan Drugs 0.000 claims 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims 4
- 229960001691 leucovorin Drugs 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 125000006501 nitrophenyl group Chemical group 0.000 claims 4
- 125000003884 phenylalkyl group Chemical group 0.000 claims 4
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 4
- NAYYNDKKHOIIOD-UHFFFAOYSA-N phthalamide Chemical compound NC(=O)C1=CC=CC=C1C(N)=O NAYYNDKKHOIIOD-UHFFFAOYSA-N 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims 4
- 229960004641 rituximab Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 4
- 229950006410 tezacitabine Drugs 0.000 claims 4
- GFFXZLZWLOBBLO-ASKVSEFXSA-N tezacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=C/F)/[C@H](O)[C@@H](CO)O1 GFFXZLZWLOBBLO-ASKVSEFXSA-N 0.000 claims 4
- 229930192474 thiophene Natural products 0.000 claims 4
- QERYCTSHXKAMIS-UHFFFAOYSA-M thiophene-2-carboxylate Chemical compound [O-]C(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-M 0.000 claims 4
- 229960000303 topotecan Drugs 0.000 claims 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 4
- 229960000575 trastuzumab Drugs 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 claims 3
- 125000001207 fluorophenyl group Chemical group 0.000 claims 3
- HKIOYBQGHSTUDB-UHFFFAOYSA-N folpet Chemical group C1=CC=C2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C2=C1 HKIOYBQGHSTUDB-UHFFFAOYSA-N 0.000 claims 3
- 125000004360 trifluorophenyl group Chemical group 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51185103P | 2003-10-16 | 2003-10-16 | |
| PCT/US2004/034185 WO2005037285A1 (en) | 2003-10-16 | 2004-10-15 | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007509059A JP2007509059A (ja) | 2007-04-12 |
| JP2007509059A5 true JP2007509059A5 (OSRAM) | 2007-09-06 |
Family
ID=34465285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535368A Pending JP2007509059A (ja) | 2003-10-16 | 2004-10-15 | 癌の処置のためのＲａｆキナーゼのインヒビターとしての、２，６−二置換キナゾリン、キノキサリン、キノリンおよびイソキノリン |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7691866B2 (OSRAM) |
| EP (1) | EP1680122A1 (OSRAM) |
| JP (1) | JP2007509059A (OSRAM) |
| KR (1) | KR20070029110A (OSRAM) |
| CN (1) | CN1882345A (OSRAM) |
| AU (1) | AU2004281154A1 (OSRAM) |
| CA (1) | CA2542329A1 (OSRAM) |
| IL (1) | IL174470A0 (OSRAM) |
| MX (1) | MXPA06003607A (OSRAM) |
| WO (1) | WO2005037285A1 (OSRAM) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| CA2359244C (en) | 1999-01-13 | 2013-10-08 | Bayer Healthcare Llc | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP2324825A1 (en) | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
| US20030216396A1 (en) | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
| UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| DE602004007382T2 (de) | 2003-05-20 | 2008-04-17 | Bayer Pharmaceuticals Corp., West Haven | Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten |
| DK1663978T3 (da) | 2003-07-23 | 2008-04-07 | Bayer Pharmaceuticals Corp | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser |
| JP4932495B2 (ja) * | 2004-01-23 | 2012-05-16 | アムゲン インコーポレイテッド | 化合物及び使用方法 |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US7652009B2 (en) | 2004-11-30 | 2010-01-26 | Amgem Inc. | Substituted heterocycles and methods of use |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US20060292537A1 (en) * | 2005-06-27 | 2006-12-28 | Arcturus Media, Inc. | System and method for conducting multimedia karaoke sessions |
| AU2006322094A1 (en) * | 2005-12-08 | 2007-06-14 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| AU2007275682B2 (en) * | 2006-07-20 | 2012-05-17 | Amgen Inc. | Substituted pyridone compounds and methods of use |
| WO2008020203A1 (en) * | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors |
| TW200829566A (en) * | 2006-12-08 | 2008-07-16 | Astrazeneca Ab | Chemical compounds |
| US20080198271A1 (en) * | 2007-02-20 | 2008-08-21 | Malki Eli | Self Operated Computerized Karaoke Recording Booth |
| CN101808999B (zh) | 2007-09-27 | 2013-02-13 | 弗·哈夫曼-拉罗切有限公司 | 用作5ht5a受体拮抗剂的喹啉衍生物 |
| GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| US20100261679A1 (en) * | 2007-10-18 | 2010-10-14 | James Sutton | CSF-1R, Inhibitors, Compositions, and Methods of Use |
| EP2226315A4 (en) | 2007-12-28 | 2012-01-25 | Carna Biosciences Inc | 2-aminoquinazoline DERIVATIVE |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP2265610B1 (en) * | 2008-02-29 | 2012-12-12 | Array Biopharma, Inc. | Pyrazole [3, 4-b]pyridine raf inhibitors |
| CN102015707A (zh) * | 2008-02-29 | 2011-04-13 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
| WO2009111277A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
| EP2265574A1 (en) * | 2008-02-29 | 2010-12-29 | Array Biopharma, Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| PL2947072T3 (pl) | 2008-03-17 | 2017-05-31 | Ambit Biosciences Corporation | 1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych |
| EP2381943A1 (en) | 2008-12-29 | 2011-11-02 | Fovea Pharmaceuticals | Substituted quinazoline compounds |
| CN102317288A (zh) | 2009-02-13 | 2012-01-11 | 佛维雅制药公司 | 作为激酶抑制剂的[1,2,4]三唑并[1,5-a]吡啶 |
| CN102573473B (zh) | 2009-06-09 | 2015-05-27 | 加利福尼亚资本权益有限责任公司 | 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物 |
| FI2440546T3 (fi) * | 2009-06-12 | 2023-03-30 | Abivax | Ennenaikaisen vanhenemisen ja erityisesti progerian hoitamiseen hyödyllisiä yhdisteitä |
| US10253020B2 (en) | 2009-06-12 | 2019-04-09 | Abivax | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging |
| KR101630283B1 (ko) * | 2009-06-25 | 2016-06-14 | 한화테크윈 주식회사 | 영상 보안 시스템에서 부호화 장치 |
| EA021275B9 (ru) | 2009-09-03 | 2015-08-31 | Байоэнердженикс | Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания |
| US8553906B2 (en) * | 2010-02-02 | 2013-10-08 | Creative Technology Ltd | Apparatus for enabling karaoke |
| TW201204723A (en) | 2010-06-22 | 2012-02-01 | Fovea Pharmaceuticals | Heterocyclic compounds, their preparation and their therapeutic application |
| HUE037860T2 (hu) | 2010-11-19 | 2018-09-28 | Ligand Pharm Inc | Heterociklusos aminok és alkalmazásuk |
| KR101858292B1 (ko) * | 2011-01-05 | 2018-05-15 | 바이오에너제닉스 | Ｐａｓｋ 억제용 헤테로시클릭 화합물 |
| CN107245056A (zh) * | 2011-08-26 | 2017-10-13 | 润新生物公司 | 化学实体、组合物及方法 |
| EP2755657B1 (en) | 2011-09-14 | 2017-11-29 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| US9249110B2 (en) | 2011-09-21 | 2016-02-02 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
| WO2013049701A1 (en) * | 2011-09-30 | 2013-04-04 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| JP6073910B2 (ja) | 2011-11-09 | 2017-02-01 | キャンサー・リサーチ・テクノロジー・リミテッド | ５−（ピリジン−２−イル−アミノ）−ピラジン−２−カルボニトリル化合物及びその治療使用 |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| EP2806874B1 (en) | 2012-01-25 | 2017-11-15 | Neupharma, Inc. | Quinoxaline-oxy-phenyl derivatives as kinase inhibitors |
| JP6027230B2 (ja) | 2012-05-15 | 2016-11-16 | キャンサー・リサーチ・テクノロジー・リミテッド | ５−［［４−［［モルホリン−２−イル］メチルアミノ］−５−（トリフルオロメチル）−２−ピリジル］アミノ］ピラジン−２−カルボニトリルおよびその治療上の使用 |
| CN104812389B (zh) | 2012-09-24 | 2020-07-17 | 润新生物公司 | 某些化学实体、组合物及方法 |
| US9725421B2 (en) | 2012-11-12 | 2017-08-08 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
| CN103896922B (zh) * | 2012-12-25 | 2017-05-03 | 上海科胜药物研发有限公司 | 新的舒尼替尼盐及其制备方法 |
| EP2757161A1 (en) | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| CN104744446B (zh) * | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| US10807983B2 (en) | 2015-03-16 | 2020-10-20 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
| JP7105774B2 (ja) | 2016-12-01 | 2022-07-25 | イグナイタ インコーポレイテッド | がん治療のための方法 |
| US11471538B2 (en) | 2017-02-10 | 2022-10-18 | INSERM (Institut National de la Santéet de la Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway |
| EP3732285A1 (en) | 2017-12-28 | 2020-11-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| CN113056272A (zh) * | 2018-09-21 | 2021-06-29 | 光谱医药公司 | 新的喹唑啉egfr抑制剂 |
| EP3669873A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
| US12528796B2 (en) * | 2019-04-15 | 2026-01-20 | Tosk, Inc. | Modulators of RAS GTPase |
| CN111072500B (zh) * | 2019-11-15 | 2022-12-06 | 山东罗欣药业集团恒欣药业有限公司 | 一种盐酸氨溴索的制备方法 |
| TW202204348A (zh) | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Ｃｈｋ１抑制劑之合成方法 |
| US12180220B2 (en) * | 2020-10-14 | 2024-12-31 | Tosk, Inc. | Heteroaryl modulators of RAS GTPase |
| US20220112178A1 (en) * | 2020-10-14 | 2022-04-14 | Tosk, Inc. | Small Molecule Modulators of RAS GTPase |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2739505A (en) * | 1952-02-04 | 1956-03-27 | Gillette Edwin | Method and means for producing composite talking pictures |
| GB900779A (en) * | 1959-04-22 | 1962-07-11 | Monsanto Chemicals | Quinazolines |
| US3177218A (en) * | 1962-01-17 | 1965-04-06 | Monsanto Chemicals | Methylene-bis(2-guanidino-4-methylquinazoline) |
| US4149190A (en) * | 1977-10-17 | 1979-04-10 | Xerox Corporation | Automatic gain control for video amplifier |
| US4408221A (en) * | 1981-09-22 | 1983-10-04 | Mccoy Reginald F H | Television chroma-key systems |
| DK190983A (da) * | 1982-05-01 | 1983-11-02 | Wellcome Found | 2,4-diamino-5-(substituerede)pyrimidiner, fremgangsmaade til deres fremstilling og mellemprodukter derfor |
| US5051817A (en) * | 1988-11-18 | 1991-09-24 | Rohm Co., Ltd. | Superimposing system |
| JP3206619B2 (ja) * | 1993-04-23 | 2001-09-10 | ヤマハ株式会社 | カラオケ装置 |
| JP3542821B2 (ja) * | 1994-03-31 | 2004-07-14 | ヤマハ株式会社 | 映像合成システムに特徴を有するカラオケ装置 |
| US5541666A (en) * | 1994-07-06 | 1996-07-30 | General Instrument | Method and apparatus for overlaying digitally generated graphics over an analog video signal |
| JP3662969B2 (ja) * | 1995-03-06 | 2005-06-22 | 富士通株式会社 | カラオケシステム |
| US5784118A (en) * | 1995-04-21 | 1998-07-21 | Sony Corporation | Video signal phase synchronizing method, circuit and synthesizing apparatus |
| US6400374B2 (en) * | 1996-09-18 | 2002-06-04 | Eyematic Interfaces, Inc. | Video superposition system and method |
| JP2957977B2 (ja) * | 1997-10-30 | 1999-10-06 | 三洋電機株式会社 | ビデオカメラ |
| US6514083B1 (en) * | 1998-01-07 | 2003-02-04 | Electric Planet, Inc. | Method and apparatus for providing interactive karaoke entertainment |
| HUP0101275A3 (en) * | 1998-03-26 | 2002-12-28 | Japan Tobacco Inc | Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists |
| US7928239B2 (en) * | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US20020072047A1 (en) * | 1999-12-13 | 2002-06-13 | Michelson Daniel R. | System and method for generating composite video images for karaoke applications |
| CN100335479C (zh) * | 1999-12-17 | 2007-09-05 | 希龙公司 | 糖元合成酶激酶3的双环抑制剂 |
| US6978051B2 (en) * | 2000-03-06 | 2005-12-20 | Sony Corporation | System and method for capturing adjacent images by utilizing a panorama mode |
| KR20020026374A (ko) * | 2000-06-20 | 2002-04-09 | 요트.게.아. 롤페즈 | 가라오케 시스템 |
| AU2001295791A1 (en) * | 2000-11-02 | 2002-05-15 | Astrazeneca Ab | 4-substituted quinolines as antitumor agents |
| ATE355272T1 (de) | 2001-04-20 | 2006-03-15 | Bayer Pharmaceuticals Corp | Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffe |
| US7035915B1 (en) * | 2001-09-05 | 2006-04-25 | Cisco Technology, Inc. | Method and apparatus for IP address assignment |
| WO2003024448A2 (en) * | 2001-09-14 | 2003-03-27 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| MXPA05011103A (es) * | 2003-04-16 | 2005-12-12 | Hoffmann La Roche | Compuestos de quinazolina. |
| US20070047834A1 (en) * | 2005-08-31 | 2007-03-01 | International Business Machines Corporation | Method and apparatus for visual background subtraction with one or more preprocessing modules |
| US7570881B2 (en) * | 2006-02-21 | 2009-08-04 | Nokia Corporation | Color balanced camera with a flash light unit |
-
2004
- 2004-10-15 US US10/966,358 patent/US7691866B2/en not_active Expired - Fee Related
- 2004-10-15 AU AU2004281154A patent/AU2004281154A1/en not_active Abandoned
- 2004-10-15 CA CA002542329A patent/CA2542329A1/en not_active Abandoned
- 2004-10-15 MX MXPA06003607A patent/MXPA06003607A/es unknown
- 2004-10-15 EP EP04795363A patent/EP1680122A1/en not_active Withdrawn
- 2004-10-15 JP JP2006535368A patent/JP2007509059A/ja active Pending
- 2004-10-15 KR KR1020067007130A patent/KR20070029110A/ko not_active Ceased
- 2004-10-15 US US10/966,073 patent/US20050084835A1/en not_active Abandoned
- 2004-10-15 WO PCT/US2004/034185 patent/WO2005037285A1/en not_active Ceased
- 2004-10-15 CN CNA200480030549XA patent/CN1882345A/zh active Pending
-
2006
- 2006-03-21 IL IL174470A patent/IL174470A0/en unknown
-
2009
- 2009-09-04 US US12/554,748 patent/US20090317359A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007507428A5 (OSRAM) | ||
| JP2005529089A5 (OSRAM) | ||
| JP2007509058A5 (OSRAM) | ||
| TW591022B (en) | Tetrahydropyridino or piperidino heterocyclic derivatives | |
| AU2009231885B2 (en) | Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use | |
| JP5576802B2 (ja) | Ｃ−Ｍｅｔチロシンキナーゼ介在疾患の治療用のイミダゾ［１，２−ｂ］ピリダジン誘導体 | |
| US7317031B2 (en) | Substituted triazole diamine derivatives as kinase inhibitors | |
| EP1682126B1 (en) | Substituted benzazoles and use thereof as inhibitors of raf kinase | |
| JP5261370B2 (ja) | キナーゼ阻害剤としてのピリジル及びピリミジニル置換されたピロール、チオフェン及びフラン誘導体 | |
| RU2515972C2 (ru) | Диазакарбазолы и способы применения | |
| MXPA05007990A (es) | Compuestos de tienopirimidina y uso de los mismos. | |
| US20040072876A1 (en) | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | |
| JP2007517843A (ja) | Ｃｈｋ１阻害剤であるチオフェン誘導体 | |
| CN109153640A (zh) | 用抗病毒剂消除乙型肝炎病毒 | |
| JP2010502717A (ja) | インターロイキン１受容体関連キナーゼの調節物質 | |
| WO2010132015A1 (en) | New compounds modulating gamma-secretase and their use in the treatment of alpha beta related pathologies, such as alzheimer's disease | |
| JP2010502716A (ja) | インターロイキン１受容体関連キナーゼの調節物質 | |
| CN103874494A (zh) | 使用pi3k/mtor的吡啶并嘧啶酮抑制剂与苯达莫司汀和/或利妥昔单抗治疗恶性血液病的组合疗法 | |
| KR20010086471A (ko) | 도파민-ｄ3-수용체 친화성을 갖는 트리아졸 화합물 | |
| JP2012530763A (ja) | Ｃｙｐ１７阻害剤としての１，３−二置換イミダゾリジン−２−オン誘導体 | |
| CN103764655A (zh) | 作为alk5和/或alk4抑制剂的经2-吡啶基取代的咪唑 | |
| KR20150138858A (ko) | 림프종 치료를 위한 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도 | |
| JP2007509059A (ja) | 癌の処置のためのＲａｆキナーゼのインヒビターとしての、２，６−二置換キナゾリン、キノキサリン、キノリンおよびイソキノリン | |
| RU2350609C2 (ru) | Производные бензофурана и бензотиофена, применяемые при лечении гиперпролиферативных заболеваний | |
| WO2005058858A1 (en) | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder |